Clinical trial
Injections of Botulinum Toxin A or Anticholinergic Treatment as First Line Therapy to Treat Neurogenic Overactive Bladder in Patients With Multiple Sclerosis
NCT04819360 is registered in ClinicalTrials.gov with Brigitte Schürch as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Injections of Botulinum Toxin A or Anticholinergic Treatment as First Line Therapy to Treat Neurogenic Overactive Bladder in Patients With Multiple Sclerosis
- Lead sponsor
- Brigitte Schürch
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- June 1, 2021
- Completion date
- April 21, 2024
- Enrollment
- 1 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.